More recently, a phase II trial showed the encouraging antitumor activity and manageable tolerability of sacituzumab tirumotecan in previously treated patients with advanced NSCLC harboring EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.